Longevity Peptides: What Does the Research Say About NAD+, Epithalon, and Glutathione?

The Honest Starting Point

"Longevity" is probably the most abused word in the supplement industry. Everything that improves a biomarker gets marketed as life-extending. So before getting into what the research actually says about NAD+, Epithalon, and Glutathione, it's worth establishing how to think about evidence quality in this area — because the gap between cell culture findings and human aging outcomes is enormous, and most of what gets sold in this space quietly papers over that gap.

The hierarchy of longevity evidence, roughly: in vitro (cell studies) at the bottom, rodent in vivo above that, non-human primate studies above that, observational human data above that, and randomized controlled human trials with hard endpoints at the top. Most longevity compound research — including for compounds discussed here — sits at the bottom two levels. That doesn't make it irrelevant. It means it should be read as mechanistic evidence, not clinical evidence.

With that said, the mechanistic findings for several of these compounds are genuinely striking.

NAD+: The Metabolic Currency That Declines With Age

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that participates in hundreds of cellular processes — most centrally, the generation of ATP through oxidative phosphorylation, and the activation of sirtuins, a family of proteins linked to DNA repair, gene expression, and stress resistance. It's sometimes called the cell's "metabolic currency" because so much depends on having adequate supplies of it.

The core finding that launched the NAD+ research wave: levels decline substantially with age. Yoshino et al. published a 2011 study in Cell Metabolism (frequently cited with the Science designation for its field impact) showing that NAD+ and its rate-limiting biosynthetic enzyme NAMPT both decrease across multiple organs in aging mice. That same study showed that replenishing NAD+ through its precursor NMN improved glucose intolerance and lipid profiles in aged mice — essentially treating some of the metabolic dysfunction associated with aging by restoring a molecule that had depleted.

The SIRT1 connection is particularly interesting. Sirtuins are NAD+-dependent: without sufficient NAD+, they can't function. SIRT1 specifically governs everything from inflammatory signaling to mitochondrial biogenesis to circadian rhythm regulation. The argument is that age-related NAD+ decline creates a kind of bottleneck for all these downstream processes simultaneously — and that maintaining NAD+ levels might preserve more youthful cellular function across multiple systems at once.

Subsequent research has identified NMN and NR (nicotinamide riboside) as NAD+ precursors with good bioavailability. Several human clinical trials have now demonstrated that oral NMN supplementation raises blood NAD+ levels in adults — the question of whether those elevated levels translate to meaningful functional improvements in humans remains partially open, though early trials are encouraging for markers of muscle function and metabolic health in older adults.

For research purposes, 22EXO's NAD+ (500mg) is available in research-grade form.

Epithalon: The Telomere Story

Epithalon (also spelled Epitalon; the tetrapeptide Ala-Glu-Asp-Gly) has an unusual origin. It was developed by Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology, part of a Soviet-era research program that produced dozens of bioregulatory peptides derived from tissue extracts. Khavinson's approach was to isolate the peptide signals that direct tissue-specific gene expression and study whether they could be used to "remind" aging cells of younger functional states. It's an unconventional framework, but the laboratory work that came out of it is real and peer-reviewed.

The landmark finding: Khavinson, Bondarev, and Butyugov reported in the Bulletin of Experimental Biology and Medicine in 2003 that adding Epithalon to telomerase-negative human fetal fibroblasts in culture induced expression of the catalytic subunit of telomerase, produced telomerase enzymatic activity, and caused measurable telomere elongation. In other words, cells that normally couldn't activate telomerase did so after Epithalon treatment — and their telomeres grew longer.

Why does this matter? Telomere length is one of the established correlates of biological aging. Each time a cell divides, telomeres shorten slightly. When they get short enough, the cell enters senescence or apoptosis. Telomerase is the enzyme that can rebuild telomere length, but in most somatic cells it's silenced after development. Khavinson's group suggested that Epithalon might reactivate this silenced enzyme — extending the functional lifespan of the cell population.

A 2025 study in Biogerontology extended this work in human cell lines, showing dose-dependent telomere length extension in normal cells through hTERT upregulation and telomerase activation. The results were more complex in cancer cell lines (Epithalon appeared to activate an alternative lengthening mechanism rather than telomerase directly), but in normal fibroblasts and epithelial cells, telomere elongation was confirmed quantitatively.

We found this distinction important: Epithalon's effect seems specific to normal cell populations, not broadly stimulating to all dividing cells. That's mechanistically reassuring, though human clinical data remains limited. Khavinson's longer-term observational work suggested benefits in cardiovascular aging markers and circadian rhythm normalization over 15-year follow-up periods — but these were not randomized controlled trials.

Epithalon (10mg) is available from 22EXO for research purposes.

Glutathione: Master Antioxidant, Not Simple Supplement

Glutathione (GSH) is often described as the body's "master antioxidant" — a term that's actually earned. It's the most abundant low-molecular-weight thiol compound synthesized in cells, present at millimolar concentrations in hepatocytes and at 1–2 mM in most other cell types. Its sulfhydryl group is what gives it reducing power: it can donate electrons to neutralize reactive oxygen species, and it participates in conjugation reactions that detoxify xenobiotics.

Forman et al., in a 2009 review in Molecular Aspects of Medicine, laid out the comprehensive biology: GSH plays critical roles in protecting cells from oxidative damage and xenobiotic toxicity, maintaining redox homeostasis, and participating in multiple regulatory signaling pathways. It is not a passive scavenger — it's actively regulated, compartmentalized, and central to cellular redox status.

Glutathione levels decline with age. This isn't controversial. Oxidative stress tends to increase with aging; GSH depletion is both a consequence and a cause of that increase, creating a feedback loop. The question for researchers is whether exogenous glutathione supplementation meaningfully raises intracellular levels — a question with a nuanced answer. Oral glutathione was long thought to have poor bioavailability because it gets cleaved in the gut. More recent work with liposomal formulations and direct IV administration has shown better delivery, and controlled studies have documented increased blood GSH levels and reduced oxidative markers following supplementation.

The clinical translation is still being worked out. Glutathione's role in liver function, immune competence, and response to oxidative challenge is well-supported by mechanistic evidence. Whether supplementing it in otherwise healthy aging adults produces meaningful outcomes beyond biomarker changes — that's a harder question with limited controlled data.

Glutathione (200mg) is available from 22EXO for research applications.

MOTS-c: The Mitochondrial Peptide Worth Knowing

MOTS-c deserves mention here because it occupies a different conceptual space from the other three. It's not a synthetic compound or a precursor — it's a peptide encoded within the mitochondrial genome itself. Discovered in 2015, MOTS-c is secreted from mitochondria and travels to the nucleus, where it regulates metabolic gene expression. Levels of MOTS-c decline with age and have been inversely correlated with metabolic disease in human studies.

Animal research has shown MOTS-c improves insulin sensitivity, enhances physical performance, and may exert anti-aging effects on metabolic function. The mechanistic story involves AMPK activation and AICAR pathway modulation — essentially, MOTS-c appears to signal a state of metabolic stress that triggers adaptive responses. Whether supplementing it in humans recapitulates these effects is an active research question.

MOTS-c (10mg) is available from 22EXO for research purposes.

Reading the Evidence Honestly

Here's the honest synthesis: the mechanistic evidence for all four compounds is real and internally consistent. NAD+ decline with aging is established; restoring levels has demonstrated metabolic benefits in animal and early human studies. Epithalon's telomere effects in human cell culture are documented. Glutathione's role in oxidative defense is among the best-established in all of redox biology. MOTS-c represents a genuinely novel insight into mitochondrial-nuclear signaling in aging.

What none of this constitutes is proof of extended human lifespan or even clear evidence of reduced morbidity in controlled human trials. The translation from "this mechanism is involved in aging" to "this compound meaningfully extends healthy human lifespan" requires clinical evidence that mostly doesn't exist yet.

Researchers in this space are best served by reading primary sources, not marketing copy — including ours. The findings are interesting. The clinical evidence is early. Both things can be true.

How to Think About Evidence Hierarchies in Longevity Research

One of the more productive things you can do as someone navigating longevity research is develop a clear mental model for what different types of evidence actually tell you. Cell culture studies are where most longevity research begins. When Khavinson's group showed that Epithalon induced telomerase in fibroblasts, that was a cell culture finding. Important — it established that the mechanism exists and can be triggered. But cells in a dish exist in a radically simplified environment compared to cells in a living organism. Every variable except the one being tested is controlled. That's the point, and also the limitation.

Rodent studies add complexity: intact immune systems, circulatory systems, endocrine interactions, aging processes that share some biology with human aging even if the timescales differ. When NAD+ precursor supplementation improved metabolic function in aged mice (Yoshino et al., Cell Metab, 2011), that was meaningful evidence of in vivo effect. Mice, however, age dramatically faster than humans, their metabolic biology differs in important ways, and interventions that extend mouse lifespan have frequently failed to translate to humans. The graveyard of compounds that extended mouse lifespan is long.

Human observational data — tracking what happens to people who happen to have higher levels of some compound — adds another layer. It's limited by confounding: people with higher NAD+ levels might differ from people with lower levels in dozens of other ways. Randomized controlled human trials are what actually establish whether an intervention works in humans. They exist for some longevity compounds in early form. For Epithalon specifically, the human data consists largely of Khavinson's long-term observational work and a handful of small clinical studies from Russian gerontological institutes — compelling in their consistency, but not designed to modern Western clinical trial standards.

None of this should be read as dismissal. The mechanistic evidence for NAD+, Epithalon, Glutathione, and MOTS-c is real and points in interesting directions. The honest position is: these are promising areas of research with solid mechanistic foundations and incomplete clinical evidence. That's a fine place for research to be — as long as researchers read it clearly rather than collapsing the gap between "interesting preclinical data" and "proven human intervention."

Practical Research Considerations

If you're investigating these compounds — whether in formal research or in an informed personal capacity — a few things are worth knowing that don't always appear in the primary literature.

NAD+ precursors vary significantly in their pharmacokinetics. NMN and NR are both NAD+ precursors but are metabolized through slightly different routes and may have different tissue distribution profiles. The debate about which is superior in humans has generated genuine controversy, with different research groups staking out positions. What's agreed: both can raise blood NAD+ levels. What's contested: which tissues benefit most, and at what doses.

Glutathione delivery remains a technical challenge. The tripeptide (glycine-cysteine-glutamate) gets partially cleaved in the gastrointestinal tract before absorption. Liposomal formulations, S-acetyl glutathione, and IV glutathione all have different absorption profiles. 22EXO's Glutathione (200mg) is formulated for research applications where delivery method can be controlled by the researcher.

Epithalon is a tetrapeptide — four amino acids — which makes it relatively easy to synthesize but also means purity verification is important. Sequence fidelity and the absence of synthetic byproducts are the key quality parameters. The research literature used peptide from well-characterized synthesis runs; researchers replicating those findings need equivalent material.

MOTS-c is larger (16 amino acids) and more structurally complex. Its stability and proper handling are more sensitive issues. Lyophilized storage under appropriate conditions is standard for maintaining activity.

For more context on Epithalon's telomere research, see our detailed piece on Khavinson's Epithalon research. Our article on MOTS-c and mitochondrial biology goes deeper on that compound. And if you're new to peptides broadly, our Peptides 101 guide provides foundational context.